



PTO/SB/21 (01-03)

Approval for use through 04/30/2003 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/750,456	
	Filing Date	Dec 28, 2000	
	First Named Inventor	Friedrich, Glenn	
	Art Unit	1632	
	Examiner Name	Anne Marie Falk	
Total Number of Pages in This Submission	16	Attorney Docket Number	LEX-0286-USA

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request (Original & Copy) <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Return Postcard - Exhibit A
Remarks		
Customer # 24231		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Lexicon Genetics Incorporated Lance K. Ishimoto Reg. No. 41,866
Signature	
Date	September 8, 2003

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: USPTO, PO Box 1450, Alexandria, VA 22231 on this date: September 8, 2003			
Typed or printed	Michelle Klein		
Signature		Date	September 8, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Friedrich *et al.* Group Art Unit: 1632

Application No.: 09/750,456 Examiner: Anne Marie Falk

Filed: December 28, 2000

Title: Novel Mutated Mammalian Cells and Animals Atty. Docket No.: LEX-0286-USA

RESPONSE TO OFFICE ACTION UNDER 37 C.F.R. §1.115

Commissioner for Patents
Alexandria, VA 22313

Sir:

Applicants acknowledge the receipt of the Office Action (Paper No. 14, "the Action") mailed on April 8, 2003 which has been carefully reviewed and studied. Reexamination and reconsideration of the application is requested in view of the following remarks. In order to facilitate the Examiner's evaluation of the application, Applicants have attempted to address the objections and rejections in the Action in the same order in which they were originally raised in Paper No. 14.

Applicants are filing herewith a Petition for Extension of Time of two months up to and including September 8, 2003 and thus the response is deemed to be timely filed. Applicants believe that no fees in addition to the fee for the extension of time are due in connection with this response. However, the Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 50-0892.

Applicants note that the patent and nonprovisional applications listed in the second sentence of the specification are not being relied upon for benefit of priority but are simply being listed for purposes of incorporating by reference the teaching contained therein. The scientific relationship between the patented technology described in the listed patents and the presently claimed invention is that the genetically engineered ES cell clone at issue was made using the patented technology